SGLT2 inhibitors are associated with minimal risk of hypoglycemia, particularly severe hypoglycemia, as a result of its insulin-independent mechanism of action, enabling it to be used as monotherapy or as a component of combination therapy with other antihyperglycemic agents (Frampton, 2018). This evidence concerns the gene SLC5A2 and Hypoglycemia.